Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company was founded by Eric J. Patzer and Vu L. Truong on April 24, 2003 and is headquartered in Los Gatos, CA.

Los Gatos, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in H.C. Wainwright & Co.'s 2022 KOL Series (Part 8) on Tuesday, November 29, at 11 a.m. EST. The KOL event will focus on the use of monoclonal antibody-based immunotherapies in infectious diseases and Aridis' Phase 3 ‘ASAP-1' study that compares the superiority of adjunctive use of the investigational, targeted immunotherapy candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of ventilator associated pneumonia (VAP) caused by Gram-positive bacteria Staphylococcus aureus (S. aureus).

Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates

Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year

Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update

On track to complete data compilation and analyses, with top-line data expected to be announced in December '22 LOS GATOS, Calif. , Oct. 4, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) announced today that patient enrollment is closed in the AR-301 Phase 3 clinical study.

Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

LOS GATOS, Calif. , Sept. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that due to adverse market conditions, it has withdrawn its proposed public offering of shares of its common stock.

Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock

LOS GATOS, Calif. , Sept. 26, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it intends to offer its common stock in a public offering.

Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates

Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif. , Aug. 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2022.

Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update

AR-701 is effective in vitro against SARS-CoV-2 Omicron subvariants, including BA.4 and BA.5 LOS GATOS, Calif. , Aug. 10, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in the lungs of infected rhesus macaques, and protected their lungs from disease.

Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates

Aridis Pharmaceuticals (ARDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing

ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Aridis Pharmaceuticals (NASDAQ:ARDS) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 2, at 7 p.m. Eastern Time (ET).

RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong

LOS GATOS, Calif. , June 3, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that Vu Truong, Ph.D.

Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates

Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif. , May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2022.

Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update

Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif. , March 31, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its fourth quarter and year ended December 31, 2021.

Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update

Aridis Pharmaceuticals Inc's (NASDAQ: ARDS) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant.  Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration.

Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study

LOS GATOS, Calif., Feb. 17, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that both of its fully human monoclonal antibodies (mAbs) in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant.

Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals

Vinco Ventures

Indonesia Energy Corp Ltd

Blink Charging

EVgo

As far as short squeeze stocks go, these five companies top the list in terms of both short interest and borrow fee rates right now. The post Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidate To Watch: Aridis Pharmaceuticals Tops List, EVgo, Indonesia Energy Corp And More

The stock price of Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) increased by over 30% during intraday trading today. This is why it happened.

Aridis Pharmaceuticals Stock (ARDS): Why The Price Surged Up Today

LOS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, received a grant award from the Bill & Melinda Gates Foundation ('Gates Foundation') to evaluate the application of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2 to people in low- and middle-income countries.

Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission

G Medical Innovations Holdings Ltd

Hillstream Biopharma

Splash Beverage Group

Thanks to continued fear and uncertainty, the stock market is down again… The post 4 Penny Stocks Up Big With The Stock Market Down Today; Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks Up Big With The Stock Market Down Today; Time To Buy?

Baudax Bio

Progenity

WiMi Hologram Cloud

Are these penny stocks on your watchlist for next week? The post Can These Penny Stocks Climb This Week?

Can These Penny Stocks Climb This Week? 4 To Watch Right Now

Kiora Pharmaceuticals

Reliance Global Group

These penny stocks climbed during premarket trading today, here's why The post 3 Penny Stocks That Exploded in Premarket Trading Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Exploded in Premarket Trading Today

ReTo Eco-Solutions

Safe Bulkers

If you're making a penny stocks watchlist right now, check these three out The post Are These Top Penny Stocks Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Aridis Pharmaceuticals Stock (ARDS)